Allschwil, Switzerland, May 16, 2024
Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage
biopharmaceutical company committed to meeting the needs of patients with severe
bacterial and fungal infections, announced today that the continued strong sales
performance of the antifungal Cresemba(®) (isavuconazole) by its license partner
Pfizer Inc. in the Asia Pacific region and China exceeded the sales threshold
triggering a USD 1.25 million milestone payment.
David Veitch, Basilea's Chief Executive Officer, stated: "This is the second
milestone payment for Asia Pacific and China in 2024 and reflects the strong
growth momentum of Cresemba in this region. We are pleased to see that Cresemba
continues to serve a medical need in patients suffering from life-threatening
invasive mold infections."
The license agreement between Basilea and Pfizer for Cresemba covers Europe
(excluding the Nordic countries) as well as 16 countries in the Asia Pacific
region and China.
Cresemba is approved and marketed in more than 70 countries, including the
United States, most EU member states and additional countries inside and outside
of Europe. According to the latest available market data, total global in-market
sales of Cresemba in the twelve months until December 2023 amounted to USD 473
million, a 26 percent growth year-on-year.(1)
About isavuconazole (Cresemba(®))
Isavuconazole is an intravenous (i.v.) and oral azole antifungal, commercialized
under the trade name Cresemba(®). Basilea has entered into several license and
distribution agreements for isavuconazole covering approximately 115 countries.
In the 27 European Union member states, as well as in Iceland, Liechtenstein,
Norway and the U.K., isavuconazole is approved for the treatment of adult
patients with invasive aspergillosis and for adult patients with mucormycosis
for whom amphotericin B is inappropriate.(2) In China, the oral and intravenous
formulations are approved for the treatment of adult patients with invasive
aspergillosis and invasive mucormycosis. Isavuconazole is also approved in the
United States and several additional countries in Europe and beyond, including
Japan.(3) It has orphan drug designation in the US, Europe and Australia for its
approved indications.
About Basilea
Basilea is a commercial-stage biopharmaceutical company founded in 2000 and
headquartered in Switzerland. We are committed to discovering, developing and
commercializing innovative drugs to meet the needs of patients with severe
bacterial or fungal infections. We have successfully launched two hospital
brands, Cresemba for the treatment of invasive fungal infections and Zevtera for
the treatment of bacterial infections. In addition, we have preclinical and
clinical anti-infective assets in our portfolio. Basilea is listed on the SIX
Swiss Exchange (SIX: BSLN). Please visit basilea.com (https://www.basilea.com/).
Disclaimer
This communication expressly or implicitly contains certain forward-looking
statements, such as "believe", "assume", "expect", "forecast", "project", "may",
"could", "might", "will" or similar expressions concerning Basilea Pharmaceutica
Ltd, Allschwil and its business, including with respect to the progress, timing
and completion of research, development and clinical studies for product
candidates. Such statements involve certain known and unknown risks,
uncertainties and other factors, which could cause the actual results, financial
condition, performance or achievements of Basilea Pharmaceutica Ltd, Allschwil
to be materially different from any future results, performance or achievements
expressed or implied by such forward-looking statements. Basilea Pharmaceutica
Ltd, Allschwil is providing this communication as of this date and does not
undertake to update any forward-looking statements contained herein as a result
of new information, future events or otherwise.
For further information, please contact:
Peer Nils Schröder, PhD
Head of Corporate Communications & Investor Relations
Basilea Pharmaceutica International Ltd, Allschwil
Hegenheimermattweg 167b
4123 Allschwil
Switzerland

 Phone  +41 61 606 1102
        media_relations@basilea.com (mailto:media_relations@basilea.com)

E-mail investor_relations@basilea.com (mailto:investor_relations@basilea.com)
This press release can be downloaded from www.basilea.com
(http://www.basilea.com).
References
1. IQVIA Analytics Link, December 2023. In-market sales reported as moving
annual total (MAT) in U.S. dollar.
2. European Public Assessment Report (EPAR) Cresemba:

    https://www.ema.europa.eu/en/medicines/human/EPAR/cresemba (Accessed: May
    15, 2024)

3. The registration status and approved indications may vary from country to
country.
Press release (PDF) (http://ml-eu.globenewswire.com/Resource/Download/fb254f45-
5bd9-408a-a59a-61cc15e41038)
Â